COVID-19, gender and estroprogestins, what do we know?

References

• Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020;20(5):533–534.
   PubMed Web of Science ®Google Scholar
• Guan W-J, Ni Z-Y, Hu Y, China Medical Treatment Expert Group for Covid-19, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–1720.
   PubMed Web of Science ®Google Scholar
• Mehta P, McAuley DF, Brown M, HLH Across Speciality Collaboration, UK, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033–1034.
   PubMed Web of Science ®Google Scholar
• Jin J-M, Bai P, He W, et al. Gender differences in patients with COVID-19: focus on severity and mortality. Front Public Heal. 2020;8:152.
   PubMed Web of Science ®Google Scholar
• Pirhadi R, Sinai Talaulikar V, Onwude J, et al. Could estrogen protect women from COVID-19? J Clin Med Res. 2020;12(10):634–639.
   PubMedGoogle Scholar
• Global Health 5050. COVID-19 sex-disaggregated data tracker n.d. https://globalhealth5050.org/the-sex-gender-and-covid-19-project/the-data-tracker/.
   Google Scholar
• Grasselli G, Zangrillo A, Zanella A, COVID-19 Lombardy ICU Network, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. JAMA. 2020;323(16):1574–1581.
   PubMed Web of Science ®Google Scholar
• Richardson S, Hirsch JS, Narasimhan M, The Northwell COVID-19 Research Consortium, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York city area. JAMA. 2020;323(20):2052–2059.
   PubMed Web of Science ®Google Scholar
• Seeland U, Coluzzi F, Simmaco M, et al. Evidence for treatment with estradiol for women with SARS-CoV-2 infection. BMC Med. 2020;18(1):369.
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–280.e8.
   PubMed Web of Science ®Google Scholar
• Dalan R, Bornstein SR, El-Armouche A, et al. The ACE-2 in COVID-19: foe or friend? Horm Metab Res. 2020;52(5):257–263.
   PubMed Web of Science ®Google Scholar
• Scully EP, Haverfield J, Ursin RL, et al. Considering how biological sex impacts immune responses and COVID-19 outcomes. Nat Rev Immunol. 2020;20(7):442–447.
   PubMed Web of Science ®Google Scholar
• Lemes RMR, Costa AJ, Bartolomeo CS, et al. 17β-estradiol reduces SARS-CoV-2 infection in vitro. Physiol Rep. 2021;9(2):1–8.
   Web of Science ®Google Scholar
• Mauvais-Jarvis F, Klein SL, Levin ER. Estradiol, progesterone, immunomodulation, and COVID-19 outcomes. Endocrinology. 2020;161(9):1–8.
   Web of Science ®Google Scholar
• Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130(5):2620–2629.
   PubMed Web of Science ®Google Scholar
• Dolhnikoff M, Duarte‐Neto AN, Monteiro ARA, et al. Pathological evidence of pulmonary thrombotic phenomena in severe COVID-19. J Thromb Haemost. 2020;18(6):1517–1519.
   PubMed Web of Science ®Google Scholar
• Tang N, Bai H, Chen X, et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;18(5):1094–1099.
   PubMed Web of Science ®Google Scholar
• Bianchi I, Lleo A, Gershwin ME, et al. The X chromosome and immune associated genes. J Autoimmun. 2012;38(2–3):J187–192.
   PubMed Web of Science ®Google Scholar
• Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016;16(10):626–638.
   PubMed Web of Science ®Google Scholar
• Trenti A, Tedesco S, Boscaro C, et al. Estrogen, angiogenesis, immunity and cell metabolism: solving the puzzle. IJMS. 2018;19(3):859.
   Google Scholar
• Phiel KL, Henderson RA, Adelman SJ, et al. Differential estrogen receptor gene expression in human peripheral blood mononuclear cell populations. Immunol Lett. 2005;97(1):107–113.
   PubMed Web of Science ®Google Scholar
• Hall OJ, Limjunyawong N, Vermillion MS, et al. Progesterone-based therapy protects against influenza by promoting lung repair and recovery in females. PLOS Pathog. 2016;12(9):e1005840.
   PubMed Web of Science ®Google Scholar
• Stelzig KE, Canepa-Escaro F, Schiliro M, et al. Estrogen regulates the expression of SARS-CoV-2 receptor ACE2 in differentiated airway epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2020;318(6):L1280–1281.
   PubMed Web of Science ®Google Scholar
• Bienvenu LA, Noonan J, Wang X, et al. Higher mortality of COVID-19 in males: sex differences in immune response and cardiovascular comorbidities. Cardiovasc Res. 2020;116(14):2197–2206.
   PubMed Web of Science ®Google Scholar
• Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397(10270):220–232.
   PubMed Web of Science ®Google Scholar
• Goërtz YMJ, Van Herck M, Delbressine JM, et al. Persistent symptoms 3 months after a SARS-CoV-2 infection: the post-COVID-19 syndrome? ERJ Open Res. 2020;6(4):00542-2020.
   PubMedGoogle Scholar
• Peghin M, Palese A, Venturini M, et al. Post-COVID-19 symptoms 6 months after acute infection among hospitalized and non-hospitalized patients. Clin Microbiol Infect. 2021;27(10): 1507–1513.
   PubMed Web of Science ®Google Scholar
• Ghosn J, Piroth L, Epaulard O, et al. Persistent COVID-19 symptoms are highly prevalent 6 months after hospitalization: results from a large prospective cohort. Clin Microbiol Infect. 2021;27:1041.e1–e1041.e4.
   PubMed Web of Science ®Google Scholar
• Calderone A, Menichetti F, Santini F, et al. Selective estrogen receptor modulators in COVID-19: a possible therapeutic option? Front Pharmacol. 2020;11:1085.
   PubMed Web of Science ®Google Scholar
• Breithaupt-Faloppa AC, Correia C de J, Prado CM, et al. 17β-Estradiol, a potential ally to alleviate SARS-CoV-2 infection. Clinics. 2020;75:e1980.
   PubMed Web of Science ®Google Scholar
• Fruzzetti F, Cagnacci A, Primiero F, et al. Contraception during coronavirus-Covid 19 pandemia. Recommendations of the board of the Italian Society of Contraception. Eur J Contracept Reprod Health Care. 2020;25(3):231–232.
   PubMed Web of Science ®Google Scholar
• Ferreira-Filho ES, de Melo NR, Sorpreso ICE, et al. Contraception and reproductive planning during the COVID-19 pandemic. Expert Rev Clin Pharmacol. 2020;13(6):615–622.
   PubMed Web of Science ®Google Scholar
• Mai V, Tan BK, Mainbourg S, et al. Venous thromboembolism in COVID-19 compared to non-COVID-19 cohorts: a systematic review with meta-analysis. Vascul Pharmacol. 2021; 139:106882.
   PubMed Web of Science ®Google Scholar
• Jiménez S, Miró Ò, Llorens P, Spanish Investigators on Emergency Situations TeAm (SIESTA) Network, et al. Incidence, risk factors, clinical characteristics and outcomes of deep venous thrombosis in patients with COVID-19 attending the emergency department: results of the UMC-19-S8. Eur J Emerg Med. 2021;28(3):218–226.
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). Coronavirus disease (COVID-19): contraception and family planning 2020. https://www.who.int/news-room/q-a-detail/coronavirus-disease-covid-19-contraception-and-family-planning.
   Google Scholar
• Ramírez I, De la Viuda E, Baquedano L, et al. Managing thromboembolic risk with menopausal hormone therapy and hormonal contraception in the COVID-19 pandemic: recommendations from the Spanish Menopause Society, Sociedad Española de Ginecología y Obstetricia and Sociedad Española de Trombosis y Hemostasia. Maturitas. 2020;137:57–62.
   PubMed Web of Science ®Google Scholar
• Dinger J, Do Minh T, Heinemann K. Impact of estrogen type on cardiovascular safety of combined oral contraceptives. Contraception. 2016;94(4):328–339.
   PubMed Web of Science ®Google Scholar
• Reed S, Koro C, DiBello J, et al. Prospective controlled cohort study on the safety of a monophasic oral contraceptive containing nomegestrol acetate (2.5mg) and 17β-oestradiol (1.5mg) (PRO-E2 study): risk of venous and arterial thromboembolism. Eur J Contracept Reprod Heal Care. 2021;0:1–8.
   PubMedGoogle Scholar
• Gaussem P, Alhenc-Gelas M, Thomas J-L, et al. Haemostatic effects of a new combined oral contraceptive, nomegestrol acetate/17β-estradiol, compared with those of levonorgestrel/ethinyl estradiol. Thromb Haemost. 2011;105(03):560–567.
   PubMedGoogle Scholar
• Junge W, Mellinger U, Parke S, et al. Metabolic and haemostatic effects of estradiol valerate/dienogest, a novel oral contraceptive: a randomized, open-label, single-centre study. Clin Drug Investig. 2011;31(8):573–584.
   PubMed Web of Science ®Google Scholar
• Caruso S, Rapisarda AMC, Minona P. Sexual activity and contraceptive use during social distancing and self-isolation in the COVID-19 pandemic. Eur J Contracept Reprod Health Care. 2020;25(6):445–448.
   PubMed Web of Science ®Google Scholar
• FSRH Clinical Effectiveness Unit. FSRH Clinical Effectiveness Unit statement: use of combined hormonal contraception during the Covid-19 pandemic. 2020. https://www.fsrh.org/documents/fsrh-clinical-effectiveness-unit-statement-use-of-combined/
   Google Scholar
• Lete I. Combined hormonal contraception and COVID-19. Eur J Contracept Reprod Health Care. 2021;26(2):128–131.
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO coronavirus (COVID-19) dashboard. Geneva: World Health Organization; 2021. https://covid19.who.int.
   Google Scholar
• Schultz NH, Sørvoll IH, Michelsen AE, et al. Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N Engl J Med. 2021;384(22):2124–2130.
   PubMed Web of Science ®Google Scholar
• Greinacher A, Selleng K, Warkentin TE. Autoimmune heparin-induced thrombocytopenia. J Thromb Haemost. 2017;15(11):2099–2114.
   PubMed Web of Science ®Google Scholar
• Greinacher A, Thiele T, Warkentin TE, et al. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med. 2021;384(22):2092–2101.
   PubMed Web of Science ®Google Scholar
• Oldenburg J, Klamroth R, Langer F, et al. Diagnosis and management of vaccine-related thrombosis following AstraZeneca COVID-19 vaccination: guidance statement from the GTH. Hamostaseologie. 2021;41(03):184–189.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency (EMA). AstraZeneca’s COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets; April 7, 2021. https://www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood.
   Google Scholar
• Agenzia Italiana del Farmaco (AIFA). Quarto Rapporto AIFA sulla sorveglianza dei vaccini COVID-19 [Fourth AIFA report on COVID-19 vaccines surveillance]; May 10, 2021. https://www.aifa.gov.it/-/quarto-rapporto-aifa-sulla-sorveglianza-dei-vaccini-covid-19.
   Google Scholar
• European Medicines Agency (EMA). COVID-19 vaccine Janssen: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets; April 20, 2021. https://www.ema.europa.eu/en/news/covid-19-vaccine-janssen-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood.
   Google Scholar
• European Medicines Agency (EMA). COVID-19 vaccine safety update; 14 April 2021. https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-comirnaty-january-2021_en.pdf.
   Google Scholar
• Carrel L, Brown CJ. When the Lyon(ized chromosome) roars: ongoing expression from an inactive X chromosome. Phil Trans R Soc B. 2017;372(1733):20160355.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency (EMA). AstraZeneca’s COVID-19 vaccine: EMA to provide further context on risk of very rare blood clots with low blood platelets; April 14, 2021. https://www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-ema-provide-further-context-risk-very-rare-blood-clots-low-blood.
   Google Scholar
• Agenzia Italiana del Farmaco (AIFA). AstraZeneca’s COVID-19 vaccine: EMA to provide further context on risk of very rare blood clots with low blood platelets; April 9, 2021. https://www.aifa.gov.it/en/-/vaccino-covid-19astrazeneca-ema-approfondisce-ulteriormente-il-rischio-di-casi-molto-rari-di-trombi-associati-a-piastrinopenia.
   Google Scholar
• International Society on Thrombosis and Haemostasis (ISTH). Statement from the ISTH on reports indicating blood clots associated with the AstraZeneca vaccine; April 9, 2021. https://www.isth.org/news/559981/.
   Google Scholar